A securities fraud class action has been filed against PROCEPT BioRobotics Corporation, and investors have until September 22, 2026 to seek lead plaintiff appointment. The lawsuit, pending in the U.S. District Court for the Northern District of California, alleges the company artificially inflated its financial performance through an extensive discount program that encouraged bulk handpiece orders far exceeding actual procedures. The complaint points to a cumulative excess field inventory of more than 10,000 units and a roughly 30% contraction in U.S. handpiece unit sales disclosed in February 2026, which contributed to an 18% stock drop over two trading days. Earlier disclosures in August and November 2025 also triggered declines of 16% and 10%, respectively. The law firm Bleichmar Fonti & Auld LLP is encouraging affected investors to contact them regarding potential claims on a contingency fee basis.
Procept Biorobotics CorpSecurities fraud class action lawsuit alleges artificial inflation of financials through discount program, leading to stock drops.